Recent headlines highlight survey findings indicating an increased risk of COVID-19 among PPI users. In this Q&A, Dr. Staller explains the COVID-19-heartburn connection, and shares his expertise on the safety of PPIs.
Departments, Centers, & Programs:
Boston, MA 02114-2696
- MD, Harvard Medical School
- MPH, Harvard T. H Chan School of Public Health
- Residency, Massachusetts General Hospital
- Fellowship, Massachusetts General Hospital
American Board Certifications
- Internal Medicine, American Board of Internal Medicine
- Gastroenterology, American Board of Internal Medicine
Accepted Insurance Plans
Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.
Dr Staller's clinical research program focuses on clinical and epidemiologic research in neurogastroenterology and motility, specifically the epidemiology of irritable bowel syndrome and chronic constipation, early life risk factors for irritable bowel syndrome, physiologic characterization of chronic constipation and bloating, the differential effects of gender on functional GI disease, the intersection between eating disorders and GI symptoms, the role of dietary and lifestyle factors in fecal incontinence, and women's health in functional GI disease.
He serves as an investigator in the MGH Clinical and Translational Epidemiology Unit (CTEU), a home for investigators from multiple disciplines using epidemiology to advance the understanding of chronic disease. He is also a member of the newly-formed Center for Neuro-intestinal Disease at MGH, a multidisciplinary group of gastroenterologists and surgeons dedicated to the advancement of the science underpinning disorders of GI motility and combining expertise in epidemiology, clinical research, translational research, and basic science into one group.
Publications (link to Pub Med): https://www.ncbi.nlm.nih.gov/pubmed/?term=Staller+K